CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 84 enrolled
Drug / intervention
Ixekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02543918
NCT02543918Phase 1Completed
CompareCT.gov

Vaccination Response Following Administration of Ixekizumab to Healthy Subjects

Eli Lilly and Company·interventional·Posted Sep 7, 2015·Updated Jan 6, 2017

In Brief

A Phase 1 clinical trial evaluating Ixekizumab, Boostrix®, and 1 other intervention for Healthy. Completed, enrolled 84 participants across 3 sites.

Detailed Summary

The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with follow-up at 12 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 7, 2015
Enrollment StartSep 1, 2015
Primary CompletionNov 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.8 years ago

Interventions

Ixekizumabdrug

Administered by SQ injection

Boostrix®drug

Administered by IM injection

Pneumovax®23drug

Administered by IM injection